Cantor Fitzgerald Reaffirms “Overweight” Rating for Affimed (NASDAQ:AFMD)

Affimed (NASDAQ:AFMD)‘s stock had its “overweight” rating restated by analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday,Benzinga reports.

A number of other brokerages have also issued reports on AFMD. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Affimed in a research report on Friday, November 15th. Stifel Nicolaus lowered their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Affimed currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Affimed Stock Performance

NASDAQ AFMD opened at $2.72 on Tuesday. The firm’s 50-day moving average is $3.43 and its two-hundred day moving average is $4.47. Affimed has a 12 month low of $2.72 and a 12 month high of $8.95. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. As a group, research analysts anticipate that Affimed will post -4.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Affimed

Several large investors have recently added to or reduced their stakes in AFMD. Choreo LLC acquired a new position in Affimed during the second quarter worth about $54,000. Intellectus Partners LLC boosted its position in shares of Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the period. Jane Street Group LLC acquired a new position in shares of Affimed in the 3rd quarter valued at $44,000. FMR LLC boosted its position in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares during the period. 30.82% of the stock is owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.